Eli Lilly shares surge 5.45% to record high

• Eli Lilly (NYSE:LLY) reportedly climbed 5.45% to an intraday record of $1,307.91 on October 20, 2026, surpassing its previous 52-week high of $1,292.65.
• Shares of Amgen, Pfizer, Johnson & Johnson and AbbVie also advanced in morning trading, while the S&P 500 Healthcare Index reportedly reached a new high.
• LSEG data cited in the market update showed 29 buy or strong-buy ratings, three holds and one sell, with a median price target of $1,380.50.

Eli Lilly (NYSE:LLY) shares surged 5.45% to a reported intraday record of $1,307.91 on Tuesday, October 20, amid a broader healthcare stock rally.

The increase surpassed the drugmaker's previous 52-week high of $1,292.65 and lifted its reported year-to-date share-price gain to approximately 21%.

Investor interest in Lilly has been supported by demand for its diabetes and weight-loss medicines, alongside expectations for continued pharmaceutical pipeline expansion.

According to LSEG data cited in the market update, 29 analysts rated Lilly buy or strong buy, three recommended holding and one rated it sell.

The company's median analyst price target stood at $1,380.50, while Lilly continued expanding its drug portfolio through acquisitions and licensing partnerships.

Other major drugmakers, including Amgen, Pfizer, Johnson & Johnson and AbbVie, also advanced in morning trading as the broader healthcare sector strengthened.

Lilly's recent dealmaking includes a drug-delivery technology agreement with Metis TechBio valued at up to $1.1 billion in potential payments.